Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: DanielleC who wrote (80951)	6/29/1999 10:59:00 AM
From: Norm Demers	Read Replies (1) \| Respond to of 119973

OSTE analyst comments: BancBoston Robertson Stephens senior medical device and medical technology analyst Wade H. King, M.D., today reiterated his Buy rating on Osteotech, Inc. (Nasdaq: OSTE). The company, headquartered in Eatontown, N.J., is a leading processor of cadaveric allograft bone for use in bone grafting procedures. "We are reiterating our Buy rating on Osteotech, following the company's announcement that it will acquire Versalok(R) Low Back Fixation System from Wright Medical Technology for $600,000, plus the cost of inventory," said King. "Following the announcement, certain uniformed investors have circulated comments that the transaction will have a negative impact on Osteotech's second quarter 1999 earnings. We believe that this view is completely erroneous, as the acquisition has been capitalized, effecting the company's balance sheet only. "In our opinion, the recent weakness in Osteotech shares represents a compelling investment opportunity," said King. "We remain confident that the company will meet our second quarter earnings per share estimate of $0.23. In addition, we look for shares of Osteotech to trade to at least 30 times our 2000 earnings per share estimate of $1.35, yielding a price target of $42. If we apply a multiple consistent with the company's 35 percent bottom-line growth rate to our earnings per share expectations, this yields a price target of $50."